ETH-LAD

ETH-LAD
Clinical data
Other namesETH-LAD; ETHLAD; 6-Ethyl-6-nor-lysergic acid diethylamide; 6-Ethyl-6-nor-LSD; N(6)-Ethyl-nor-LSD; 9,10-Didehydro-N,N,6-triethylergoline-8β-carboxamide
Routes of
administration
Oral
Drug classSerotonin receptor agonist; Serotonergic psychedelic; Hallucinogen
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
  • Illegal in France
Pharmacokinetic data
Onset of action15 minutes–1 hour
Duration of action8–12 hours
Identifiers
  • (6aR,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-
    hexahydroindolo-[4,3-fg]quinoline-9-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H27N3O
Molar mass337.467 g·mol−1
3D model (JSmol)
  • CCN(C([C@@H]1C=C2C3=CC=CC4=C3C(C[C@H]2N(CC)C1)=CN4)=O)CC
  • InChI=1S/C21H27N3O/c1-4-23(5-2)21(25)15-10-17-16-8-7-9-18-20(16)14(12-22-18)11-19(17)24(6-3)13-15/h7-10,12,15,19,22H,4-6,11,13H2,1-3H3/t15-,19-/m1/s1 checkY
  • Key:MYNOUXJLOHVSMQ-DNVCBOLYSA-N checkY
  (verify)

ETH-LAD, or ETHLAD, also known as 6-ethyl-6-nor-LSD, is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD; also known as METH-LAD). It is slightly more potent than LSD and is among the most potent psychedelics known. The drug is taken orally.

It acts as a serotonin receptor agonist, including of the serotonin 5-HT2A receptor. In addition, it binds to dopamine receptors. The drug produces psychedelic-like effects in animals. It is closely structurally related to LSD and to other psychedelic lysergamides like PRO-LAD and AL-LAD.

ETH-LAD was first described in the scientific literature by 1976. Its effects in humans were assessed and reported by Alexander Shulgin in the 1980s and 1990s. The drug was encountered as a novel recreational designer drug in Europe by 2016. In addition, a prodrug of ETH-LAD, 1P-ETH-LAD, has been developed and encountered as a designer drug.